Ezetimibe plus fenofibrate: A new combination therapy for the management of mixed hyperlipidaemia?

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1345-1352

  Farnier, Michel ^a  

^a Point Médical ^*  (France)

Author keywords

Cardiovascular disease; Ezetimible; Fenofibrate; HDL cholesterol; LDL cholesterol; Mixed hyperlipidaemia; Triglyceride

Indexed keywords

ATORVASTATIN; CHOLESTEROL ACYLTRANSFERASE; COLESTYRAMINE; COUMARIN; CREATINE KINASE; CREATININE; CYCLOSPORIN; DIGOXIN; DRUG METABOLITE; ETHINYLESTRADIOL; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANOPARTICLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GENETIC CODE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID ABSORPTION; LIVER FUNCTION TEST; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PANCREATITIS; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; DRUG COMBINATION; REVIEW;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; PROCETOFEN;

EID: 34250837432     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1345     Document Type: Article

References (60)

1. DURRINGTON P: Dyslipidaemia. Lancet (2003) 362:717-731.
2. PACKARD CJ: Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr. Opin. Lipidol. (2006) 17:412-417.
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
4. THE TASK FORCE ON DIABETES AND CARDIOVASCULAR DISEASES OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD): Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart J. (2007) 28:88-136.
5. GRUNDY SM, CLEEMAN JI, MERZ CNB et al. FOR THE COORDINATING COMMITTEE OF THE NATIONAL CHOLESTEROL EDUCATION PROGRAM: Implications or recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110:227-239.
6. DE BACKER G, AMBROSIONI E, BORCH-JONSEN K et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. (2003) 24:1601-1610.
7. ROBINS SJ, COLLINS D, WITTES JT et al. FOR THE VA-HIT STUDY GROUP: Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: a randomized controlled trial. JAMA (2001) 285(12):1585-1591.
8. RUBINS HB, ROBINS SJ, COLLINS D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. (2002) 162:2597-2604.
9. TENENBAUM A, MOTRO M, FISMAN EZ et al.: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. (2005) 165:1154-1160.
10. THE BIP STUDY GROUP: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. the Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102:21-27.
11. THE FIELD STUDY INVESTIGATORS: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet (2005) 366(9500):1849-1861.
12. FARNIER M: Combined therapy with a HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am. J. Cardivasc. Drugs (2003); 3(3):169-178.
13. CORSINI A, BELLOSTA S, DAVIDSON MH: Pharmacokinetic interactions between statins and fibrates. Am. J. Cardiol. (2005) 96(Suppl.): 44K-49K.
14. ALSHEIKH-ALI AA, KUVIN JT, KARAS RH: Risk of adverse events with fibrates. Am. J. Cardiol. (2004) 94:935-938.
15. JONES PH, DAVIDSON MH: Reporting rate of rhadomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. (2005) 95:120-122.
16. SHEPHERD J: The role of the exogenous pathway in hypercholesterolemia. Eur. Heart J. (2001) 3(Suppl. E): E2-E5.
17. CATAPANO AL: Ezetimibe: a selective inhibitor of cholesterol absorption. Eur. Heart J. (2001) 3(Suppl.): E6-E10.
18. SUDHOP T, LUTJOHANN D, VON BERGMANN K. Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol. Ther. (2005) 105:333-341.
19. ALTMANN SW, DAVIS Jr HR, ZHU L et al. Niemann-Pick C1-Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303:1201-1204.
20. GARCIA-CALVO M, LISNOCK JM, BULL HG et al.: The target of ezetimibe is Niemann-Pick C1-Like1 (NPC1L1). Proc Natl. Acad. Sci. USA (2005) 102(23):8132-8137.
21. DAVIES JP, IOANNOU YA: The role of the Niemann-Pick C1-Like1 protein in the subcellular transport of multiple lipids and their homeostasis. Curr. Opin. Lipidol. (2006) 7:221-226.
22. SMART EJ, De ROSE RA, FARBER SA: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA (2004) 101(10):3450-3455.
23. JEU LA, CHENG JWM: Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin. Ther. (2003) 25(9):2352-2387.
24. GHOSAL A, HAPANGAMA N, YUAN Y et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab. Dispos. (2004) 32(3):314-320.
25. VAN HEEK M, FARLEY C, COMPTON DS et al.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. (2000) 129:1748-1754.
26. DARKES MJM, POOLE RM, GOA KL: Ezetimibe. Am. J. Cardiovasc. Drugs (2003) 3(1):67-76.
27. SUDHOP T, LUTJOHANN D, KODAL A et al.: Inhibition of intestinal cholesterol absorption by czetimibe in humans. Circulation (2002) 106:1943-1948.
28. FRUCHART JC, BREWER HB, LEITERSDORF E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am. J. Cardiol. (1998) 81:912-917.
29. FRUCHART JC, STAELS B, DURIEZ P: The role of fibric acids in atherosclerosis. Curr. Atheroscl. Rep. (2001) 3:83-92.
30. STAELS B, DALLONGEVILLE J, AUWERX J, SCHOONJANS K, LEITERSDORF E, FRUCHART JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98:2088-2093.
31. FAZIO S, LINTON MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscl. Rep. (2004) 6:148-157.
32. ADKINS JC, FAULDS D: Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs (1997) 54(4):615-633.
33. KEATING GM, ORMROD D: Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs (2002) 62(13):1909-1944.
34. KEATING GM, CROOM KF: Fenofibrate. A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs (2007) 67(1):121-153.
35. CHAPMAN MJ: Fibrates: therapeutic review. Br. J. Diabetes Vasc. Dis. (2006) 6(1):11-18.
36. GUERIN M, BRUCKERT E, DOLPHIN PJ et al.: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. (1996) 16(6):763-772.
37. FRUCHART JC, DURIEZ P: Mode of action of fibrates in the regulation of triglycerides and HDL-cholesterol metabolism. Drugs Today (2006) 42(1):39-64.
38. KOSOGLOU T, STATKEVICH P, FRUCHART JC et al.: Pharmacodynamic and pharmacokinetic interaction between fenofibrate and czetimibe. Curr. Med. Res. Opin. (2004) 20(8):1197-1207.
39. STEIN E: Results of Phase I/II clinical trials with ezetimibe, a novel selective cholesterol6 absorption inhibitor. Eur. Heart J. (2001) 3(Suppl. E): E11-E16.
40. DUJOVNE CA, ETTINGER MP, McNEER JF et al. FOR THE EZETIMIBE STUDY GROUP: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. (2002) 90:1092-1097.
41. KNOPP RH, GITTER H, TRUITT T et al. FOR THE EZETIMIBE STUDY GROUP: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. (2003) 24:729-741
42. BAYS HE, MOORE PB, DREHOBL MA et al. FOR THE EZETIMIBE STUDY GROUP: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. (2001) 23(8):1209-1230.
43. KOH KK, HAN SH, QUON MJ et al.: Benefical effects of fenofibrate to improve endothelial dysfunction and raise adinopectin levels in patients with primary hypertriglyceridemia. Diabetes Care (2005) 28(6):1419-1424.
44. CAPELL WH, DeSOUZA CA, POIRIER P et al.: Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. (2003) 23:307-313.
45. LIAMIS G, BAIRAKTARI ET, ELISAF MS: Effect of fenofibrate on serum uric acid levels. Am. J. Kidney Dis. (1999) 34: 594.
46. TSIMICHODIMOS V, BAIRAKTARI E, ELISAF M: Fibrate-induced increase in serum urea and creatinine levels. Nephrol. Dial. Transplant (2002) 17(4):682.
47. DIERKES J, WESTPHAL S, LULEY C: Fenofibrate-induced hyperhomocysteinaemia. Clinical implications and management. Drug Saf. (2003) 26(2):81-91.
48. DIABETES ATHEROSCLEROSIS INTERVENTION STUDY INVESTIGATORS: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet (2001) 357(9260):905-910.
49. VAKKILAINEN J, STEINER G, ANSQUER JC et al.: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation (2003) 107:1733-1737.
50. GENEST J, FROHLICH J, STEINER G: Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of c1oronary artery disease in type 2 diabetes mellitus. Am. J. Cardiol. (2004) 93(7):848-853.
51. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
52. COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al. ON BEHALF OF THE CARDS INVESTIGATORS: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696.
53. SYVANNE M, WHITTALL RA, TURPEINEN U et al.: Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis (2004) 172:267-272.
54. FRICK MH, ELO O, HAAPA K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. (1987) 317:1237-1245.
55. MIKAEL LG, GENEST J Jr, ROZEN R: Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. (2006) 98:564-571.
56. ANSQUER JC, FOUCHER C, RATTIER S, TASKINEN MR, STEINER G, DAIS INVESTIGATORS: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. (2005) 45(3):485-493.
57. UNDAS A, BROZEK J, SZCZEKLIK A: Homocysteine and thrombosis: from basic science to clinical evidence. Thromb. Haemost. (2005) 94:907-915.
58. FARNIER M, FREEMAN MW, MacDONELL G et al.: Efficacy and safety of the co-administration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur. Heart J. (2005) 26:897-905.
59. McKENNEY JM, FARNIER M, LO KW et al.: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. (2006) 47(8):1584-1587.
60. CHOLESTEROL TREATMENT TRIALIST'S (CTT) COLLABORATORS: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet (2005) 366:1267-1278.